Diabetic Nephropathy Articles & Analysis
10 news found
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as ...
It occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. ...
“Their cumulative experience with public and private biotech companies will be of great value to us as we advance our vision of serving patients suffering from Diabetic Kidney Diseases and Fibrosis with our new class of CB1 inverse agonists”, added Dr. ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as ...
The therapeutic effects of a peripheral CB1 blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs. About Diabetic Kidney Disease Diabetic Kidney Disease (DKD) occurs when diabetes causes damage to the glomeruli and proximal ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive ...
In particular, there was a marked, dose-dependent reduction in albuminuria in this model of diabetes and associated kidney injury. “The study showed that treatment with INV-202 reduced the progression of nephropathy in STZ-induced diabetic mice. ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive ...